# Dyslipidemia Drugs Market and Forecast 2025-2033

Limited-Time Offer \[Flat 15% Discount\] [Dismiss](#)

[Skip to content](#content "Skip to content")

[Updated Data Matrix Available](https://www.ihealthcareanalyst.com/research-services/)

Market Value | Market Volume | Epidemiology | Clinical Trials | Patent Landscape | Regulatory Approvals

[Home](https://www.ihealthcareanalyst.com/) » [Reports](https://www.ihealthcareanalyst.com/shop/) » [Pharmaceuticals](https://www.ihealthcareanalyst.com/reports/pharmaceuticals/)

![Awaiting product image](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)

![Awaiting product image](https://www.ihealthcareanalyst.com/wp-content/uploads/2019/08/report-icon4-e1565791186498.png)

# Dyslipidemia Drugs Market by Drug Class (Product/Brand) – Bile Acid Binding Resins \[Colestid (colestipol), Prevalite / Locholest / Questran (cholestyramine), Welchol (colesevelam)\], Fibrates \[Lopid (gemfibrozil), TriCor / Trilipix / Lipidil (fenofibrate), Lovaza (omega-3-acid ethyl esters), Triglide, Fibricor, Vascepa (icosapent ethyl)\], Niacins / Vitamin B3 Aagonist \[Niacor, Niaspan, Slo-Niacin\], PCSK9 Inhibitors \[Praluent (alirocumab), Repatha (evolocumab)\], Statins \[Pravachol (pravastatin), Zocor (simvastatin), Lescol (fluvastatin), Lipitor (atorvastatin), Crestor (rosuvastatin), Livazo / Livalo / Alipza / Vezepra (pitavastatin)\], Selective Cholesterol Absorption Inhibitor \[Zetia (ezetimibe)\], ATP Citrate Lyase Inhibitors \[Nexletol (bempedoic acid), Nexlizet (bempedoic acid + ezetimibe)\], Small Interfering RNA Therapy \[Leqvio (inclisiran)\], Combination Therapies \[Vytorin (ezetimibe + simvastatin), Caduet (amlodipine + atorvastatin), Atozet (ezetimibe + atorvastatin), Rosuzet (ezetimibe + rosuvastatin)\], Pipeline Analysis and Forecast 2025-2033

$3,000.00

## Report Specifications: Market Size, Market Share, Growth Trends, Forecast, Geography

Dyslipidemia is a chronic metabolic syndrome, characterized by improper level of low density lipoprotein, high density lipoprotein, and triglycerides. Dyslipidemia has emerged as a major health concern across the world.

The major effects of the lipid lowering drugs include lowering of serum low density lipoprotein (LDL) cholesterol levels which are believed to predispose to atherosclerosis and its complications, acute myocardial infarction, cerebrovascular ischemic stroke and peripheral vascular disease.

There are four classes of lipid-lowering drugs in the market include the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins), the fibrates (gemfibrozil, clofibrate, and fenofibrate), niacin/nicotinic acid, and the bile acid binding resins (colestipol and cholestyramine).

Statins class includes a wide range of compounds such as atorvastatin (Lipitor), fluvastatin (Lescol), rosuvastatin (Crestor), paravastatin, simvastatin, pitavastatin, lovastatin, and others. Bile acid resins are available as generic drugs such as cholestyramine (Questran, Locholest and Prevalite), colesevelam (Welchol) and colestipol (Colestid).

Fibric acid and omega-3 fatty acid derivatives include Fenofibrate, Gemfibrozil, and Vascespa. Niacins include Niacor, Niaspan, and Slo-Niacin. Other combination drugs include atorvastatin and amlodipine (Caduet), lovastatin and niacin, simvastatin and ezetimibe (Vytorin) and cholesterol absorption inhibitors like ezetimibe (Zetia).

The global dyslipidemia drugs market report estimates the market size ($million 2023 to 2033), market share, market trends forecast (CAGR% 2025 to 2033).

The global market for dyslipidemia drugs segmented by drug class (product/brand) – bile acid binding resins \[Colestid (colestipol), Prevalite / Locholest / Questran (cholestyramine), Welchol (colesevelam)\], fibrates \[Lopid (gemfibrozil), TriCor / Trilipix / Lipidil (fenofibrate), Lovaza (omega-3-acid ethyl esters), Triglide, Fibricor, Vascepa (icosapent ethyl)\], niacins / vitamin B3 agonist \[Niacor, Niaspan, Slo-Niacin\], PCSK9 inhibitors \[Praluent (alirocumab), Repatha (evolocumab)\], statins \[Pravachol (pravastatin), Zocor (simvastatin), Lescol (fluvastatin), Lipitor (atorvastatin), Crestor (rosuvastatin), Livazo / Livalo / Alipza / Vezepra (pitavastatin)\], selective cholesterol absorption inhibitor \[Zetia (ezetimibe)\], ATP citrate lyase inhibitors \[Nexletol (bempedoic acid), Nexlizet (bempedoic acid + ezetimibe)\], small interfering RNA therapy \[Leqvio (inclisiran)\], combination therapies \[Vytorin (ezetimibe + simvastatin), Caduet (amlodipine + atorvastatin), Atozet (ezetimibe + atorvastatin), Rosuzet (ezetimibe + rosuvastatin)\], pipeline analysis, and geography.

The global dyslipidemia drugs market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.

The global dyslipidemia drugs market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.

Major players operating in the global dyslipidemia drugs market and included in this report are AbbVie, Inc. (Abbott Laboratories, Inc.), Amarin Corporation plc, Amgen, Inc., Aralez Pharmaceuticals, Inc., Astellas Pharma, Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Daiichi Sankyo Co., Ltd., Esperion Therapeutics, Inc., Kowa Pharmaceuticals, Inc., Merck & Co., Inc., Novartis AG, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A., and Shionogi & Co., Ltd.

**DATA INCLUDED:** Dyslipidemia Drugs Market Size, Dyslipidemia Drugs Market Share, Dyslipidemia Drugs Market Growth Rates, Dyslipidemia Drugs Market Trends, and Dyslipidemia Drugs Market Forecast to 2033

**Market Data:**

*   Estimation Base Year: 2024
*   Historical Data Range: 2023-2024
*   Forecast Period: 2025-2033
*   Market Representation: Revenue in $million and CAGR % from 2025 to 2033
*   Regional Scope: North America, Europe, Asia Pacific, Latin America, Rest of the World (Middle East & Africa)
*   Country Scope: U.S., Canada, U.K., Germany, France, Italy, Spain, Japan, China, India, South Korea, Brazil, Mexico, South Africa, South Korea, Saudi Arabia, UAE, and other countries.
*   Report Coverage: Revenue forecasts, company market share, competitive landscape analysis, growth factors, and market trends
*   Customization Scope (15% Free): Accommodation of specific or custom requirements beyond the current report scope.

**Qualitative Analysis:**

*   Industry Overview
*   Industry Trends
*   Market Driver, Restraints, and Opportunities
*   Market Size
*   Growth Trends
*   Porter’s Five Forces Analysis
*   Market Attractiveness Matrix
*   Competitive Landscape
    *   Company Overview
    *   Financial Performance
    *   Product Portfolio
    *   Strategic Insights
    *   Recent Developments

**Quantitative Analysis:**

*   Market Size Projections: Comprehensive estimates and forecasts for all segments
*   Regional Market Analysis: Estimates and forecasts for key countries
*   Corporate Financial Performance: Analysis of company financials
*   Competitive Landscape: Market share analysis of leading companies

Choose License Type

Choose an optionSingle-user LicenseMulti-user LicenseCorporate License[Clear](#)

Dyslipidemia Drugs Market by Drug Class (Product/Brand) – Bile Acid Binding Resins \[Colestid (colestipol), Prevalite / Locholest / Questran (cholestyramine), Welchol (colesevelam)\], Fibrates \[Lopid (gemfibrozil), TriCor / Trilipix / Lipidil (fenofibrate), Lovaza (omega-3-acid ethyl esters), Triglide, Fibricor, Vascepa (icosapent ethyl)\], Niacins / Vitamin B3 Aagonist \[Niacor, Niaspan, Slo-Niacin\], PCSK9 Inhibitors \[Praluent (alirocumab), Repatha (evolocumab)\], Statins \[Pravachol (pravastatin), Zocor (simvastatin), Lescol (fluvastatin), Lipitor (atorvastatin), Crestor (rosuvastatin), Livazo / Livalo / Alipza / Vezepra (pitavastatin)\], Selective Cholesterol Absorption Inhibitor \[Zetia (ezetimibe)\], ATP Citrate Lyase Inhibitors \[Nexletol (bempedoic acid), Nexlizet (bempedoic acid + ezetimibe)\], Small Interfering RNA Therapy \[Leqvio (inclisiran)\], Combination Therapies \[Vytorin (ezetimibe + simvastatin), Caduet (amlodipine + atorvastatin), Atozet (ezetimibe + atorvastatin), Rosuzet (ezetimibe + rosuvastatin)\], Pipeline Analysis and Forecast 2025-2033 quantity 

Buy Report   

For inquiries regarding discounts on single or bundled report purchases, please reach out to us.

*   [Table of Contents PH](#tab-table-of-contents-ph)
*   [Market Segments and Companies](#tab-market-segments-and-companies)
*   [Request ToC / Sample](#tab-request-toc-sample-discount)

1.  **Introduction**
2.  **Executive Summary**
    *   Market Size Estimation ($million, 2023-2033)
    *   Forecast Estimation ($million and CAGR%, 2025-2033)
3.  [**Research Methodology**](https://www.ihealthcareanalyst.com/research-methodology/)
4.  **Market Landscape**
    *   Market Dynamics
        *   Drivers
        *   Barriers
        *   Opportunities
    *   Market Share Analysis
        *   Companies
        *   Drugs
    *   Market Trends Analysis
        *   Key success factors
        *   Market Growth Rate
    *   Market Attractiveness Analysis
    *   Market Profitability Analysis
        *   Buyer power
        *   Supplier power
        *   Barriers to entry
        *   Threat of substitute products
        *   Rivalry among firms in the industry
    *   Distribution Channels
5.  **Market Segmentation** \[_refer Market Segments and Companies Tab_\]
    *   Drug Class or Drug (Brand) Type
    *   Drug or Disorder Test
    *   Indication Type
    *   Drug Treatment
    *   Mechanism of Action
    *   Therapeutic Area or Nature of Application
    *   End User Groups
6.  **Geography (Region, Country)**
    *   North America (U.S., Canada)
    *   Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    *   Asia Pacific (Japan, China, India, Rest of APAC)
    *   Latin America (Brazil, Mexico, Rest of LA)
    *   Rest of the World (Middle East & Africa)
7.  **Regulatory Overview** 
    *   IND, NDA filed, FDA, EMEA Approvals
8.  **Pipeline Analysis** (Phase 1, 2 and 3 Drugs)
    *   Phase 3 Drugs Forecast Estimation (Approval to 2033)
    *   Phase 1 and 2 Drugs – Qualitative Analysis
9.  **Company Profiles** \[_refer Market Segments and Companies Tab_\]
    *   Company Overview
    *   Financial Snapshot
    *   Product Portfolio
    *   Business Strategies
    *   Recent Developments
10.  **Recommendations**
11.  **References**

**Key Questions Answered:**  
1\. What are the factors driving and limiting this market, key success factors and challenges?  
2\. Which are the leading competitors in the market, their market share, profitability and key trends by product, technology, services portfolio?  
3\. How do markets perform between countries and regions?  
4\. What market segments are contributing to maximum share and greatest growth?  
5\. What is the product or procedure volumes by country and regions?

**Actionable Insights Included:**  
1\. Product portfolio matrix (Share vs. Growth)  
2\. Market attractiveness (Region vs. Growth)  
3\. Spot matrix (Product vs. Region)  
4\. Geographic distribution matrix (Share vs. Growth)

**Dyslipidemia Drugs Market**

1\. **Drug Class (Product/Brand)**  
1.1. Bile Acid Sequestrants / Bile Acid Binding Resins  
1.1.1. Colestid (Colestipol)  
1.1.2. Prevalite / Locholest / Questran (Cholestyramine)  
1.1.3. Welchol (Colesevelam)  
1.2. Fibrates (Fibric Acid and Omega-3 Fatty Acid Derivatives)  
1.2.1. Lopid (gemfibrozil)  
1.2.2. TriCor / Lipidil (fenofibrate / fenofibric acid)  
1.2.3. Triglide (fenofibrate)  
1.2.4. Trilipix (fenofibrate)  
1.2.5. Fibricor (fenofibrate)  
1.2.6. Vascepa (icosapent ethyl)  
1.3. Niacins (Nicotinic Acid) / Vitamin B3 Agonist  
1.3.1. Niacor (niacin)  
1.3.2. Niaspan (niacin)  
1.3.3. Slo-Niacin  
1.4. PCSK9 Inhibitors / Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor  
1.4.1. Praluent (alirocumab)  
1.4.2. Repatha (evolocumab)  
1.5. Statins \[3‑hydroxy‑3‑methylglutaryl-coenzyme‑A (HMG‑CoA) Reductase Inhibitor\]  
1.5.1. Pravachol (pravastatin)  
1.5.2. Zocor (simvastatin)  
1.5.3. Lescol (fluvastatin)  
1.5.4. Lipitor (atorvastatin)  
1.5.5. Crestor (rosuvastatin)  
1.5.6. Livazo / Livalo / Alipza / Vezepra (pitavastatin)  
1.6. Selective Cholesterol Absorption Inhibitor  
1.6.1. Zetia (ezetimibe)  
1.7. ATP Citrate Lyase (ACL) Inhibitors  
1.7.1. Nexletol (bempedoic acid)  
1.7.2. Nexlizet (bempedoic acid + ezetimibe)  
1.8. Small Interfering RNA (siRNA) Therapy  
1.8.1. Leqvio (inclisiran)  
1.9. Combination Therapies / Fixed Dose Combinations (FDCs)  
1.9.1. Vytorin (ezetimibe + simvastatin)  
1.9.2. Caduet (amlodipine + atorvastatin)  
1.9.3. Atozet (ezetimibe + atorvastatin)  
1.9.4. Rosuzet (ezetimibe + rosuvastatin)

2\. **Pipeline Analysis**

3\. **Geography**  
3.1. North America (U.S., Canada)  
3.2. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)  
3.3. Asia Pacific (Japan, China, India, Rest of APAC)  
3.4. Latin America (Brazil, Mexico, Rest of LA)  
3.5. Rest of the World

4\. **Company Profiles**  
4.1. AbbVie, Inc. (Abbott Laboratories, Inc.)  
4.2. Amarin Corporation plc  
4.3. Amgen, Inc.  
4.4. Aralez Pharmaceuticals, Inc.  
4.5. Astellas Pharma, Inc.  
4.6. AstraZeneca plc  
4.7. Bristol-Myers Squibb Company  
4.8. Daiichi Sankyo Co., Ltd.  
4.9. Esperion Therapeutics, Inc.  
4.10. Kowa Pharmaceuticals, Inc.  
4.11. Merck & Co., Inc.  
4.12. Novartis AG  
4.13. Pfizer, Inc.  
4.14. Regeneron Pharmaceuticals, Inc.  
4.15. Sanofi S.A.  
4.16. Shionogi & Co., Ltd.

**Request Table of Contents / Sample Report**

Full Name\*

Company Email\*

Phone Number\* \[Please add country code\]

Subject\*

Message\*

Resource Links

*   [About Us](https://www.ihealthcareanalyst.com/about/)
*   [Clinical Trials](https://www.ihealthcareanalyst.com/clinical-trials-dashboard/)
*   [Drugs@FDA](https://www.ihealthcareanalyst.com/drugs-fda-dashboard/)
*   [Orange Book](https://www.ihealthcareanalyst.com/orange-book-dashboard/)
*   [Premarket Approval](https://www.ihealthcareanalyst.com/premarket-approval-pma/)
*   [Premarket Notification](https://www.ihealthcareanalyst.com/premarket-notification-510k/)
*   [Publications](https://www.ihealthcareanalyst.com/publications/)

Terms and Conditions

*   [FAQs](https://www.ihealthcareanalyst.com/faqs/)
*   [Careers](https://www.ihealthcareanalyst.com/careers/)
*   [Terms of Use](https://www.ihealthcareanalyst.com/terms/)
*   [How to Order](https://www.ihealthcareanalyst.com/order/)
*   [Return Policy](https://www.ihealthcareanalyst.com/return/)
*   [Privacy Policy](https://www.ihealthcareanalyst.com/privacy/)
*   [Disclaimer Policy](https://www.ihealthcareanalyst.com/disclaimer/)

Secure Online Payment

![iHealthcareAnalyst, Inc.](https://www.ihealthcareanalyst.com/wp-content/uploads/2018/07/creditcard-payment-logos-300x48.jpg)

Search

Search

Contact Address

**US Office:** 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043, United States  
Phone: +1 (314) 315-4764  
**India Office:** 5, Shilpa Chambers, Opp. J. M. Road, Shivajinager, Pune 411005, India  
Phone: +91 (20) 25898524  
Email: [\[email protected\]](/cdn-cgi/l/email-protection#5f2c3e333a2c1f36373a3e332b373c3e2d3a3e313e33262c2b713c3032)

[](# "Scroll back to top")

Search for: